This is a first-in-human, phase I/II trial of the selective RET inhibitor selpercatinib (LOXO-292) in individuals with advanced solid tumors harboring RET alterations, including non-small-cell lung cancer and medullary thyroid cancer.
Results
A report from the trial – presented at the 2018 ASCO Annual Meeting – showed that the agent has “robust” antitumor activity against RET-altered cancers.
Updated data presented at the World Conference on Lung Cancer 2019 demonstrated that selpercatinib elicits deep antitumor responses and is well tolerated by patients with advanced NSCLC harboring RET fusions.